BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 8.11 -0.04 (-0.49%) Market Cap: 1.68 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

BioCryst Pharmaceuticals Inc to Discuss the Phase 1 trial of BCX9930 - Conference Call Transcript

Oct 28, 2019 / 12:30PM GMT
Release Date Price: $2.44 (+3.83%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst Pharmaceuticals Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to turn your call over to John Bluth of BioCryst. You may begin.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thank you very much, Kevin. Good morning, and welcome to our call to discuss data from our Phase I trial of BCX9930. Today's press release and accompanying slides, which include data from the Phase I trial in healthy volunteers, are available on our website.

Participating on the call with me today are CEO, Jon Stonehouse; and Chief Medical Officer, Dr. Bill Sheridan. Our CFO, Tom Staab; and our Chief Business Officer, Megan Sniecinski, are also here and will be available during our Q&A session.

Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot